Another one of AstraZeneca’s more left-field product candidates, its investigational lupus therapy anifrolumab, has disappointed at Phase III.
The first of two Phase III TULIP trials of AstraZeneca PLC/MedImmune LLC’s investigational lupus therapy, anifrolumab, has missed its primary endpoint, casting the program in doubt.
Top-line data from the 52-week TULIP 1 study in adult patients with moderate-to-severe systemic lupus erythematosus (SLE) show the drug...
The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Oral RNA splicing modulator has gone into a Phase II/III trial
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
